Understand the diagnosis, the value of tumor samples, and the difference between established care and research options. You do not have to sort it all out alone.
GBM is an aggressive cancer that starts in the brain. Tissue testing helps confirm the diagnosis and guide care.
Ask your team: “What is my exact diagnosis, and which results are still pending?”
Glioblastoma, or GBM, is an aggressive cancer that starts in the brain and can grow into nearby brain tissue.
MRI helps locate and monitor it. Tissue examined after surgery or a biopsy usually confirms the diagnosis and provides information about the tumor’s molecular features.
Learn more: American Cancer Society: GBM and diagnosis ↗
GBM contains different cell populations. Surgery removes tumor, but infiltrating GBM cells can remain in surrounding brain tissue and contribute to recurrence. Radiotherapy and chemotherapy can shape which cells survive: resistant populations may expand, cells may adapt, and molecular features may change.
These processes vary between people. They do not establish why an individual tumor changed. Understanding the first sample is a starting point; following the tumor over time matters too.
Ask which DNA, RNA and protein tests can help characterize the tumor and inform care or trial eligibility. Broad profiling is not automatically useful for every patient; the team should explain what each result could change.
Microbiome analysis may be relevant within research, but it is not validated for routine GBM treatment decisions. Discuss sample preservation with your clinical team.
SNO/EANO: molecular testing ↗ · Longitudinal proteogenomics study ↗ · Microbiome: current evidence and limits ↗
Your team follows MRI, symptoms, neurological examinations and other tests when appropriate, comparing them with earlier findings. Additional tissue or other samples may help when clinically justified; a new biopsy is not automatic. Treatment effects can also resemble progression on scans.
The aim is to recognize changes and anticipate the next clinical decision as early as the evidence allows. Monitoring cannot guarantee that we can predict the tumor’s evolution or always stay one step ahead.
EANO: monitoring and follow-up ↗ · SNO/EANO: response assessment ↗
IDH: helps classify the tumor. In current adult classification, glioblastoma is IDH-wildtype; an IDH-mutant grade 4 astrocytoma is a different diagnosis.
MGMT promoter methylation: can help estimate likely benefit from temozolomide. It is one part of a treatment discussion, not a guarantee of response.
Before surgery, ask how tissue can safely be collected and preserved. After surgery, ask what is stored and which tests could help.
Ask your team: “What tissue is available, and what could testing change?”
Whether surgery is ahead of you or already behind you, there is a useful conversation to start with your care team.
Ask the hospital’s pathology department, through your care team, what tissue blocks, slides, frozen material or other samples remain. Confirm their availability, quality and which tests they can support. Request the pathology and molecular reports. The opportunity to learn is not automatically lost.
Ask the surgeon and pathology team whether tissue can be collected and preserved for clinically useful tests or appropriate research. Agree the purpose, consent, receiving laboratory, handling, transport, costs and timing before the procedure when feasible. Diagnosis and safety come first.
These conversations can inform an early, proactive plan alongside standard care. Samples do not guarantee a treatment option, trial access, benefit or a predictable strategy.
NCI: pathology reports and stored tissue ↗ · RANO: tissue sampling and processing ↗
Validated tests can help characterize the available tumor sample and start a proactive conversation with your neuro-oncology team.
IDH testing helps establish the tumor’s diagnosis and classification. MGMT promoter methylation helps estimate likely benefit from temozolomide. DNA/RNA panels may identify additional molecular alterations when clinically indicated.
Different biomarkers answer different questions: diagnosis, prognosis or potential treatment relevance. A finding is not automatically a treatment target. An accurate laboratory result does not guarantee that a matching treatment will help or be available.
SNO/EANO: diagnosis and molecular testing ↗ · NCI: interpreting biomarker results ↗
Testing characterizes the material examined, not every cell or every region of the tumor. GBM can differ across regions and evolve over time. A “whole-genome” test reads DNA from the sampled material; it does not map the entire tumor.
Useful results depend on the sample’s type, amount, quality and handling, as well as the test and clinical question. Fixed tissue, frozen tissue and living cells serve different purposes. One format cannot support every analysis.
MRI, symptoms and clinical examinations add information that a tissue result cannot provide. Liquid biopsy remains limited in GBM and does not routinely replace tissue diagnosis. Additional sampling requires a clinical reason and a safety assessment.
NCI: sampling and changing biomarkers ↗ · NCI: sample formats ↗
Get your reports, confirm what tissue remains, and ask the team to connect those findings to the care plan, possible trials and follow-up. Be proactive alongside evidence-based treatment.
Newly diagnosed glioblastoma has an established, evidence-based treatment pathway called Standard of Care. For many adults who can tolerate combined treatment, the core protocol is:
The core pathway is well established, rather than a completely different protocol for every patient. Age, overall health, tumor findings and personal goals can require adjustments. If GBM returns, there is no single standard next treatment.
Discuss an appropriate clinical trial early. Depending on the study, a trial may add to standard care or test an alternative; it does not automatically replace standard care. Eligibility, timing, risks and possible benefits need review with your team.
Explore glioblastoma trials on ClinicalTrials.gov ↗ · A listing does not confirm eligibility, availability or benefit.
Ask your team: “What is my Standard of Care protocol, and is there a suitable clinical trial to consider before treatment starts?”
Educational information, not an individual treatment prescription. Your treating team should explain the plan and any changes.
Tumor findings may inform targeted treatments or trial discussions. A molecular match or personalized design does not guarantee access or benefit.
Ask your team: “Is this established care, off-label treatment or research?”
“Personalized” describes how an approach is chosen or designed. It does not, by itself, tell you whether it is approved, proven or right for you.
Care supported by clinical evidence and adapted to the person. For many eligible adults, this includes maximal safe surgery, then radiation with temozolomide, followed by further temozolomide.
The plan can differ with age, functional status, molecular findings and personal goals. Tumor Treating Fields may be discussed in some settings; recommendations and access vary by country.
Molecular testing sometimes identifies a feature that could be targeted by a drug. Such findings are uncommon in GBM, and a molecular match does not guarantee benefit.
The specific drug might have an approved indication, be considered off-label, or be available only in a trial. Your team should make that distinction explicit.
These approaches aim to help the immune system recognize and attack tumor cells. Some use an individual’s tumor or cells; others target features shared by many tumors.
The mechanism, clinical evidence, risks and route to access differ. A personalized design or an immune response is not, by itself, proof of clinical benefit.
Ask your team about eligibility and treatment timing. A trial is an option to evaluate, not a promise of access or benefit.
These are treatment vaccines, not vaccines to prevent GBM. Their aim is to help immune cells recognize tumor targets and control disease. Understanding the mechanism is a starting point; clinical benefit has to be demonstrated separately.
Targets may be chosen from the person’s tumor profile, or a product may be made using their tumor material or immune cells. “Personalized” does not mean every tumor cell is covered, or that the treatment will work.
A vaccine may target proteins or other features found in multiple patients. It still needs to fit the individual. These categories overlap: a person’s own dendritic cells can be used to present a shared target.
The goal is an effective, lasting immune response that improves outcomes. A blood-test immune response is not the same as longer survival or better quality of life. Small, single-arm or external-control studies cannot answer the same questions as a well-conducted randomized comparison. Do not rank vaccines by survival numbers from different studies.
Effects can include injection-site reactions, fever and fatigue. Serious allergic or inflammatory effects are also possible, depending on the approach. Cell collection, electroporation, surgery and partner drugs add different burdens. Ask for the actual protocol’s adverse-event data, monitoring plan and symptoms requiring urgent contact.
Eligibility can depend on diagnosis, disease stage, prior treatment, steroid use, general health, target/HLA requirements and sample quality. Confirm manufacturing time, trial slots, country rules, visits, travel and costs with the clinical team and study site. Do not change steroids to pursue a vaccine.
NCI: treatment vaccines and side effects ↗ · General overview, 24 Sep 2019; reviewed 8 Nov 2026.
These examples use different kinds of personalization. Open only the approach you want to understand.
How it aims to work. Tumor DNA/RNA and protein analysis guide a patient-specific set of peptide targets, including mutated and non-mutated antigens, intended to stimulate T cells.
What has been shown. The sponsor describes a platform and an initial trial in triple-negative breast cancer. This is not evidence of benefit in GBM; claims about broader use remain an aim, not a demonstrated GBM outcome.
Access & practical questions. An open GBM study or routine GBM access was not established in the source reviewed. Ask about the actual GBM protocol, required sample, manufacturing time, costs and oversight before making plans.
Sponsor’s platform and clinical description ↗ · reviewed 8 Nov 2026
How it aims to work. Tumor sequencing identifies mutations that can be used to design patient-specific peptides. The goal is to teach T cells to recognize these tumor-associated targets.
What has been shown. A 2024 observational report described 173 vaccinated GBM patients and immune responses in tested patients. It was not a randomized comparison; selection and other treatments can influence survival. The findings support further study, not a reliable estimate of benefit for an individual.
Access & practical questions. The report describes individual treatment attempts, which are distinct from an approved standard treatment or trial enrollment. cecava’s page describes preparation of a Phase 1/2 study, not confirmed open recruitment. Verify tissue suitability, manufacturing, cost and the applicable treatment framework.
Nature Communications, 11 Aug 2024 ↗ · Current clinical-program description ↗
How it aims to work. A DNA vaccine encodes selected neoantigens from the patient’s tumor. Delivery uses electroporation, brief electrical pulses that help cells take up the DNA, with an IL-12 immune-stimulating component.
What has been shown. A 2026 Phase 1, single-arm study vaccinated nine patients with newly diagnosed, MGMT-unmethylated GBM after surgery and radiation. It reported feasibility and immune activity, with no serious adverse events reported. Its size and lack of a randomized control group do not establish a survival benefit or exclude uncommon harms.
Access & practical questions. The published cohort is not an enrollment offer. Ask whether any current protocol fits the diagnosis and timing, what material is needed, and what the injections/electroporation involve. Present availability was not confirmed.
Nature Cancer, 12 May 2026 ↗ · Indexed abstract and linked correction ↗
How it aims to work. The patient’s own dendritic cells, immune cells that present targets to T cells, are loaded with broken-down tumor material (lysate). This is patient-specific cell manufacturing, rather than selection of only a few mutations.
What has been shown. The 2022 report found a survival association using external control groups. Those comparisons are not equivalent to a conventional concurrent randomized efficacy analysis and can be affected by differences between groups. Uncommon serious events considered at least possibly related included brain swelling, nausea and lymph-node infection.
Access & practical questions. Ask a specialist to verify current regulatory status and any lawful access route in the relevant country. Tissue availability, immune-cell collection, manufacturing and travel matter. This page does not establish present access or personal eligibility.
How it aims to work. The patient’s dendritic cells are loaded with tumor-derived RNA and lysate to present a broad range of targets. The described protocol includes injections near cervical lymph nodes and type I interferon to support an immune response.
What has been shown. The sponsor describes clinical studies assessing safety and efficacy. A plausible immune mechanism does not prove that this treatment extends survival, and the full treatment combination has its own risks.
Access & practical questions. The sponsor lists a GBM Phase 2 study, NCT06805305, but a place and eligibility must be checked with a study site. The expanded-access program is explicitly not open. Ask about tissue needs, immune-cell collection, injections and interferon-related effects.
Sponsor’s mechanism and access policy ↗ · reviewed 8 Nov 2026
How it aims to work. The patient’s tumor cells are treated with an antisense molecule directed at IGF-1R, irradiated and placed in temporary biodiffusion chambers. The intended effect is an immune response to tumor material, not reinjection of untreated live tumor cells.
What has been shown. The sponsor’s randomized Phase 2b study enrolled 99 patients. Its primary endpoint, progression-free survival, did not reach statistical significance. Overall survival was a secondary finding; encouraging signals need confirmation. The sponsor reported no drug-related serious adverse events, which does not make the procedure risk-free.
Access & practical questions. The approach requires coordinated surgery, tissue processing and temporary chamber placement/removal. In September 2026, the sponsor described a Phase 3 study planned for 2027, dependent on financing. That is not confirmed recruitment or current access.
NCI mechanism ↗ · Sponsor results, 2 Dec 2025 ↗ · Development update, 15 Sep 2026 ↗
A shared target is not the same as universal eligibility. Some products still require individualized cell manufacturing.
How it aims to work. A peptide-mimic vaccine aims to stimulate immunity against survivin, a protein expressed by many tumors. It is a shared-target approach rather than a bespoke vaccine made from each patient’s mutations. MimiVax is a different company and treatment from Imvax.
What has been shown. In the sponsor’s SURVIVE Phase 2b update, the primary overall-survival comparison did not reach statistical significance. A younger-patient subgroup signal needs confirmation. Serious adverse events occurred in both arms; an “immune” treatment is not automatically harmless.
Access & practical questions. The sponsor states that SURVIVE is no longer enrolling and SurVaxM is not available outside clinical trials. Any future protocol must confirm eligibility and access; this page is not an access offer.
Sponsor’s mechanism ↗ · SURVIVE results and access update ↗ · reviewed 8 Nov 2026
How it aims to work. ITI-1000 uses the patient’s dendritic cells loaded with pp65-LAMP RNA. ITI-1001 uses DNA plasmids encoding CMV-associated antigens, delivered with electroporation. These illustrate how patient-specific cells can carry shared targets. The presence and role of CMV in GBM remain debated.
What has been shown. The sponsor describes investigational clinical programs, including a Phase 1 ITI-1001 study. The biological rationale and early research do not establish clinical benefit for an individual patient.
Access & practical questions. Ask about the precise product and protocol, antigen requirements, cell collection or electroporation, treatment timing and monitoring. Current recruitment and access were not confirmed here.
ITI-1000 / dendritic-cell approach ↗ · ITI-1001 DNA approach ↗ · reviewed 8 Nov 2026
How it aims to work. These DNA-based approaches target hTERT, WT1 and PSMA, tumor-associated antigens shared across patients. The programs include an IL-12 immune-stimulating component and are studied with checkpoint-blocking drugs; INO-5412 combines INO-5401 and INO-9012 in one vial.
What has been shown. The current pipeline lists Phase 2 GBM programs. A combination’s outcome cannot be attributed to the vaccine alone. Neither a listed development phase nor complementary mechanisms establish benefit, safety or that the combination is right for a particular patient.
Access & practical questions. Current enrollment was not confirmed. Ask which protocol is active, whether it matches newly diagnosed or recurrent disease, and about the full combination’s immune-related risks, delivery procedure and monitoring.
Sponsor’s current pipeline ↗ · reviewed 8 Nov 2026
Source and access review: 8 November 2026. Selected examples, not a ranking or an exhaustive list. Publications and sponsor updates are identified separately. Availability can change; an active pipeline or a published study does not confirm a treatment slot. No combination is recommended solely because its mechanisms sound complementary.
Ask how its target, evidence, risks and practical requirements fit your diagnosis and current plan. A trial or other lawful access route requires an individualized clinical discussion, not a promise of benefit.
Regular reviews of MRI scans and symptoms help patients and caregivers track changes and prepare the next decision.
Ask your team: “What will we monitor, and who should we call?”
Urgent symptoms: new seizures, sudden weakness, speech difficulty or reduced consciousness need urgent medical assessment. Use local emergency services for severe or sudden symptoms.
Your clinical team sets the timing of your treatment. Choose questions and take them to your appointment. For the proposed coordination process, see the Pilot workflow.
With the patient’s permission, a caregiver can join visits, take notes, organize records, track questions and help with daily tasks. Ask for a nurse navigator or social worker, practical support and a backup caregiving plan.
Rehabilitation, symptom relief, emotional support and palliative care can be discussed alongside cancer treatment. Palliative care is not the same as stopping treatment.
Ask your team for a written symptom and seizure plan, after-hours contacts and guidance on medicines, driving and daily safety.
New seizures, sudden weakness or speech trouble, or reduced consciousness need urgent medical assessment. Use local emergency services for severe or sudden symptoms.
Precision care depends on the physical infrastructure and operational capabilities to preserve tissue, generate evidence and coordinate physician-led review. A pilot is needed to evaluate how these capabilities work together before standardizing the process.
Patient-initiated, institution-operated and physician-governed. Treatment decisions remain with the treating team.
Pilot-design note: The steps below are an initial working proposal and current best estimate. Participating physicians and sites, together with the pilot’s designated clinical or governance body, will review and update the final workflow, inputs, outputs, and quality criteria for each deliverable. No final protocol or approval is implied; urgent clinical decisions remain with the treating teams.
The next step is to establish feasibility, responsibilities and measurable milestones.
That a coordinated process can preserve opportunities for appropriate testing, organize results into traceable evidence, and make the next physician-led review easier to prepare.
This is a feasibility objective. It is not a claim that the platform improves survival or selects an effective treatment.
Protocol, participating roles, consent, privacy, eligibility, scope and costs.
Document specimen coordination, testing status and evidence review in the agreed pilot.
Report completion, delays, usability, limitations and what should change before expansion.
An itemized budget, funding target and delivery dates are not yet finalized in this proposal.
The next conversation should make the scope, responsible parties and costs explicit.
No payment is collected. No tax-deductibility, investment return or institutional partnership is represented.
Prepare a conversation, without making a commitment.
A coordinated pathway for evaluation across centers, connecting tissue planning, molecular and functional evidence, physician-led review, and access to appropriate care and research.
Running multiple well-governed pilots in parallel could accelerate rigorous evaluation of the technologies. Study designs, site commitments and budgets remain to be agreed.
Professional and public-research signals are converging around functional precision medicine and patient-derived models. That creates an opening to build and evaluate a coordinated process, while clinical, regulatory and reimbursement questions remain.
NCI’s August 2026 commentary reports recent ASCO support for advancing modern functional precision medicine. This supports development and evaluation; it is not a blanket clinical recommendation for every assay.
NCI report · 6 August 2026 ↗NCI identifies the need to preserve living tissue, standardize handling and assays, and generate rigorous evidence for approval and reimbursement pathways. These are concrete priorities for process design and prospective evaluation.
NCI workshop perspective ↗NIH announced contracts for its Standardized Organoid Modeling Center in September 2025. Initial work covers liver, lung, heart and intestine models. This is broader research infrastructure, not funding for this program or evidence of GBM efficacy.
NIH announcement · 25 September 2025 ↗A 2026 systematic review covered 21 studies and 15,547 real-world patients. Costs were standardized to 2024 U.S. dollars using inflation and purchasing-power adjustments.
Cumulative direct medical cost in a commercially insured cohort; about $18K per patient per month.
Cumulative cohort estimate
A direct-cost estimate from a high-income European system. It is not a uniform European cost or a matched comparison.
Direct-cost study estimate
Modeled lifetime cost; about $900 per patient per month. This is not an observed U.S.-style cumulative total.
Modeled lifetime estimate
Rounded figures. Different populations, payers and time horizons. These figures are not a comparable global price range and do not show equivalent outcomes or savings from this program. Christopher et al. · 2026 systematic review ↗
The existing GBM Precision planning model estimates annual U.S. payer-paid direct medical spending. This is a directional scenario, not an observed national total or a market-revenue forecast.
U.S. annual direct medical spending · 2024 USD.
Per patient-year · four-cohort weighted mean.
12–18 active months × the model’s claims-cost range.
New U.S. diagnoses per year · model input.
Florida as an example. Local planning estimates illustrate the distance between diagnosis, testing and access. They do not define where investor funding will be deployed or establish access rates for other regions.
Planning range: 700–850 per year
Planning range: 560–680 per year
Planning range: 55–95 per year
Planning range: 55–80 per year
Planning range: 10–30 per year · inferred estimate
Evidence review: GBM Precision Investor Evidence Brief, pp. 2–3. Florida counts remain planning estimates, not observed statewide data. The brief discusses the ≈83% and ≈3% assumptions; local validation is still needed.
Read the math: 620 ÷ 750 ≈ 83%; 20 ÷ 750 ≈ 3%. Categories overlap; these are not linked statewide observations or successive conversion rates. Do not add the shares or divide them to estimate an achievable increase.
Measure next: Tissue preservation, reasons for losses, actual access and outcomes. This graphic does not estimate coordination’s effect, survival gain or financial return.
Per patient-year · four-cohort weighted mean.
Modeled input · $8K–$18K range
Illustrative modeled scenario
Illustrative modeled scenario
Illustrative modeled scenario
Illustrative modeled scenario
The Skill helps organize questions and sources. It does not replace the physician’s assessment.
This small deterministic example demonstrates claim tracing. It contains no Rafael case data and is not a run of the full Skill.
“Explain why a single tumor sample may not capture all tumor-cell states. Do not recommend treatment.”
This fixed output is built into the prototype. Clicking again produces the same content; no AI request or patient upload is made.
A citation is not a clinical endorsement. Every substantive claim needs verification, and decisions remain with the treating team.
A longitudinal case, including patient-reported treatment updates, presented for education and discussion with the treating team.